Company Information

  

Address: 1616 EASTLAKE AVE. E
SUITE 310 
City: SEATTLE 
State: WA 
Zip Code: 98102 
Telephone: (206) 682-0645 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage immunotherapy company with next-generation, diversified in vivo approaches designed to enable the body's immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have designed our technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer via distinct mechanisms. Our two lead product candidates, CMB305 and G100, utilize different immuno-oncology approaches that, we believe, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action. We have also been executing a strategy to partner individual indications outside of oncology in infectious and allergic diseases, which provide potential downstream economics while preserving growth opportunity in the future.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-2.19NAN/E
03/2017-2.36NAN/E
12/2016-2.47NAN/E
09/2016-2.53NAN/E
06/2016-2.28NAN/E
03/2016-2.11NAN/E
12/2015-2.06NAN/E
09/2015-1.16NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.19Total Liab/Total Assets0.17
Net Inc/Total Assets-0.47Total Liab/Inv Cap0.20
Net Inc/Inv Cap-0.56Total Liab/Comm Equity0.07
Pretax Inc/Net Sales-4.04Interest Coverage RatioNA
Net Inc/Net Sales-4.04Curr Debt/EquityNA
Cash Flow/Net Sales-2.70LTD/EquityNA
SG&A/NetSales1.65Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover5.71Quick Ratio5.89
Inventory Turnover1.55Current Ratio5.92
Inventory Day Sales0.00Net Rec/Curr Assets0.03
Net Sales/Work Cap0.14Inv/Curr Assets0.01
Net Sales/PP&E32.03  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.73 5.47 2.06 8.21
Cost of Goods Sold 0.02 0.04 0.13 0.07
Selling & Admin Exps 3.89 4.14 4.44 9.55
Operating Income -14.04 -12.75 -14.52 -12.59
Interest Exp NA NA NA NA
Pretax Income -13.85 -12.62 -14.45 -12.44
Other Income 0.19 0.13 0.08 0.15
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -13.85 -12.62 -14.45 -12.44

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 87.28 95.91 107.26 112.47
Receivables - Total 0.62 0.75 3.67 7.49
Inventories - Total 0.62 0.58 0.61 0.71
Total Current Assets 89.84 99.15 114.08 125.23
Net Property, Plant & Equipment 0.51 0.54 0.41 0.43
Total Assets 90.87 99.88 114.50 125.66
Liabilities        
Accounts Payable 9.97 7.48 9.49 9.56
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 17.25 14.75 19.26 17.09
Long-Term Debt NA NA NA NA
Total Liabilities 17.33 14.82 19.32 18.40
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -210.36 -196.52 -183.74 -169.29
Treasury Stock NA NA NA NA
Total Stockholders' Equity 73.54 85.07 95.18 107.26
Total Liabilities and Stockholders' Equity 90.87 99.88 114.50 125.66

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -8.66 -17.38 -4.38 -10.92
Net Cash Provided by Investing Activities 15.94 -0.20 -20.35 -0.02
Net Cash Provided by Financing Activities 0.11 0.29 -0.49 30.85

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20122.96-10.84--
12/20131.60-15.98--
12/20146.43-34.15-4.56
12/20159.51-39.44-2.06
12/201613.26-53.53-2.47
Growth Rates45.48----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/176913,18751.47




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.